Massive validation of NanoDX's technology (of which Sensera forms a core part) with the IBM collaboration agreement. The product just got a whole lot more 'real' and IMO EUA approval risk has decreased substantially.
From the Bioworld article: 'This marks IBM’s first collaboration to allow a medical device company to use its nanoscale technology'... 'IBM’s initial goal of developing its nanosensor technology to advance sensor CMOS technology can now come to fruition. “Through Nanodx, IBM Research’s innovative nanoscale technology may now play a crucial part in rapid tests for COVID-19 and other health conditions,” Zafar said.' It's fair to say IBM see the potential on offer here and Sensera have their seat and will strap in for the ride.
The IBM CMOS nano-biosensors are different to what Sensera provide. There are numerous types of sensors that would go into a product such as this. Sensera's microfluidic sensors read the biomarkers in the bodily fluid sample and are the 'lab-on-a-chip' component in the cartridge.
Cheers
SE1 Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
